Magagnoli, J.;                     Narendran, S.;                     Pereira, F.;                     Cummings, T.H.;                     Hardin, J.W.;                     Sutton, S.S.;                     Ambati, J.    
        Association between Fluoxetine Use and Overall Survival among Patients with Cancer Treated with PD-1/L1 Immunotherapy. Pharmaceuticals 2023, 16, 640.
    https://doi.org/10.3390/ph16050640
    AMA Style
    
                                Magagnoli J,                                 Narendran S,                                 Pereira F,                                 Cummings TH,                                 Hardin JW,                                 Sutton SS,                                 Ambati J.        
                Association between Fluoxetine Use and Overall Survival among Patients with Cancer Treated with PD-1/L1 Immunotherapy. Pharmaceuticals. 2023; 16(5):640.
        https://doi.org/10.3390/ph16050640
    
    Chicago/Turabian Style
    
                                Magagnoli, Joseph,                                 Siddharth Narendran,                                 Felipe Pereira,                                 Tammy H. Cummings,                                 James W. Hardin,                                 S. Scott Sutton,                                 and Jayakrishna Ambati.        
                2023. "Association between Fluoxetine Use and Overall Survival among Patients with Cancer Treated with PD-1/L1 Immunotherapy" Pharmaceuticals 16, no. 5: 640.
        https://doi.org/10.3390/ph16050640
    
    APA Style
    
                                Magagnoli, J.,                                 Narendran, S.,                                 Pereira, F.,                                 Cummings, T. H.,                                 Hardin, J. W.,                                 Sutton, S. S.,                                 & Ambati, J.        
        
        (2023). Association between Fluoxetine Use and Overall Survival among Patients with Cancer Treated with PD-1/L1 Immunotherapy. Pharmaceuticals, 16(5), 640.
        https://doi.org/10.3390/ph16050640